A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis

BACKGROUND: The mesenchymal-epithelial transition factor (MET) receptor is dysregulated in hepatocellular carcinoma (HCC), and tivantinib (ARQ 197) is an oral, selective, MET inhibitor. METHODS: This Phase-1b study assessed tivantinib safety as primary objective in patients with previously treated H...

Descripción completa

Detalles Bibliográficos
Autores principales: Santoro, A, Simonelli, M, Rodriguez-Lope, C, Zucali, P, Camacho, L H, Granito, A, Senzer, N, Rimassa, L, Abbadessa, G, Schwartz, B, Lamar, M, Savage, R E, Bruix, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553536/
https://www.ncbi.nlm.nih.gov/pubmed/23287988
http://dx.doi.org/10.1038/bjc.2012.556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553536/
https://www.ncbi.nlm.nih.gov/pubmed/23287988
http://dx.doi.org/10.1038/bjc.2012.556

Ejemplares similares